Magenta Therapeutics

July 12, 2018
Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

[vc_row][vc_column][vc_column_text]The Drug Development IPO market enjoyed a strong second quarter, with over $2.54B raised by 26 companies across the globe. 85% of companies that listed during […]
Contact Us